Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

PHASE4CompletedINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
HIVAIDSSmoking Cessation
Interventions
DRUG

Algorithm Treatment

Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.

OTHER

Quitline only

eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.

Trial Locations (1)

35209

University of Alabama, Birmingham, Birmingham

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Harvard University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT03670316 - Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care | Biotech Hunter | Biotech Hunter